BS_F8N6CFQE
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 22.536136662286463
- age_years
- 3.208
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_014EVM2D | low-grade glioma | — | 0.968 |
| 2 | BS_V89HGTET | pilocytic astrocytoma | — | 0.960 |
| 3 | BS_MF9X3PKH | low-grade glioma | — | 0.955 |
| 4 | BS_JWSR581E | low-grade glioma | — | 0.949 |
| 5 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.943 |
| 6 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.942 |
| 7 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.942 |
| 8 | BS_55JW3HFM | Ganglioglioma | — | 0.940 |
| 9 | BS_52426AMF | low-grade glioma | — | 0.940 |
| 10 | BS_S7CZY2CH | low-grade glioma | — | 0.938 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.532 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.526 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.498 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.473 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.451 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.449 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.447 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.442 | Idelalisib | — uncovered |
| COMPLEMENT | 0.436 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.416 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.385 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.377 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.331 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.329 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.246 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.238 | Inavolisib | — uncovered |